Survodutide vs CagriSema: Two Investigational Obesity Drugs Compared

Survodutide and CagriSema are both investigational obesity drugs, but they come from different companies and use different hormone combinations. Survodutide (Boehringer Ingelheim and Zealand Pharma) pairs GLP-1 with glucagon to suppress appetite and raise energy burn, and it stands out for its effects on liver disease. CagriSema (Novo Nordisk) pairs GLP-1 with amylin to control appetite from two angles, and it’s already under FDA review. Neither is FDA approved, and neither is available to prescribe or buy, including through TrimRx, outside of clinical trials.

What Is Survodutide?

Survodutide (development code BI 456906) is a once-weekly injection that activates two receptors, GLP-1 and glucagon. The GLP-1 side curbs appetite and slows digestion, the same mechanism as semaglutide. The glucagon side is the twist: it nudges the body to burn more energy and pushes the liver to break down stored fat.

In its Phase 2 obesity trial, survodutide produced about 15% mean weight loss at 46 weeks (and close to 19% in the on-treatment analysis), with the weight curve still falling at the end. Its standout result came in a Phase 2 trial for MASH (a serious fatty liver disease), where higher doses improved liver fibrosis in roughly 35% to 40% of participants versus 22% on placebo, and cut liver fat substantially. Survodutide is in Phase 3 (the SYNCHRONIZE program) for both obesity and liver disease.

What Is CagriSema?

CagriSema is Novo Nordisk’s fixed-dose combination of semaglutide 2.4 mg (a GLP-1 drug) and cagrilintide 2.4 mg (an amylin analog), delivered in one weekly injection. Instead of adding glucagon, it adds amylin, a fullness hormone, to GLP-1.

In its REDEFINE 1 Phase 3 trial, CagriSema produced about 20% to 23% weight loss at 68 weeks depending on the analysis. Novo Nordisk submitted it to the FDA in December 2025, with a decision expected by late 2026. One caveat: in a head-to-head trial against tirzepatide (REDEFINE 4), CagriSema fell short, posting about 23% weight loss versus tirzepatide’s 25.5% and missing its target of matching the approved drug.

Survodutide vs CagriSema at a Glance

The Key Differences

Glucagon versus amylin

Both build on GLP-1, then add a different second hormone. Survodutide adds glucagon, which raises energy expenditure and targets liver fat. CagriSema adds amylin, which reinforces the fullness signal. The glucagon route gives survodutide its liver advantage; the amylin route gives CagriSema strong appetite control. Different tools, different strengths, and a good example of how the field is testing combinations beyond GLP-1 alone.

Weight loss

On the numbers available, CagriSema currently shows higher weight loss, with Phase 3 figures in the low 20s percent versus survodutide’s mid-to-high teens in Phase 2. But the comparison isn’t clean: survodutide’s data is earlier-stage and its curve hadn’t leveled off, so its final Phase 3 number could land higher. CagriSema has the more mature evidence today.

Liver disease

This is survodutide’s clearest edge. Its glucagon activity drives the liver to burn fat, which is why its MASH results are notable. CagriSema is built for weight and metabolic control, not specifically for liver fibrosis. For someone whose main concern is fatty liver disease, survodutide is the more targeted candidate, though again, it’s not available.

How close to market

CagriSema is ahead. It’s already under FDA review and could be approved as soon as late 2026. Survodutide is still working through Phase 3, with a possible FDA submission in 2026 or later and potential approval around 2027 to 2028. Neither is a near-term option you can start today.

Why Neither Is Available Yet

Both are investigational. CagriSema is awaiting an FDA decision; survodutide is still in trials. That means no prescriptions and no legal compounded versions (compounding applies to approved drugs). Peptides sold online as survodutide or a cagrilintide combination have no quality, sterility, or dosing oversight and aren’t a safe or legal stand-in. The trial doses here describe what researchers used under medical supervision, not a routine you can replicate.

What You Can Do Today

While these drugs move through development, effective approved treatments are already here. Tirzepatide and semaglutide deliver substantial weight loss now, and tirzepatide outperformed CagriSema head-to-head; the kind of results tirzepatide can produce is well documented. Starting an approved option today means progress now, with the flexibility to switch later if something better is approved.

A licensed provider can help you find the medication that fits your situation. TrimRx’s intake quiz is an easy place to begin.

This article is for general educational purposes only and is not medical advice. Survodutide and CagriSema are investigational; survodutide has not been approved by the FDA, and CagriSema is under FDA review and not yet approved. Neither is available by prescription or through TrimRx, and any product marketed online as either compound outside a clinical trial is unregulated and potentially unsafe. Weight loss figures reflect clinical trial findings and are not guarantees of individual results. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment, and never attempt to self-source or self-administer an investigational medication.